Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2a, Open-Label, Multi-Center Study Evaluating the Safety and Anti-Tumor Activity of Ex Vivo Expanded, Autologous Natural Killer Cells (SNK01) in Combination With Trastuzumab or Cetuximab in Subjects With Advanced/Metastatic HER2- or EGFR-Expressing Cancers

NCT04464967 is registered in ClinicalTrials.gov with NKGen Biotech, Inc. as lead sponsor.

NCT NCT04464967
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04464967 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2a, Open-Label, Multi-Center Study Evaluating the Safety and Anti-Tumor Activity of Ex Vivo Expanded, Autologous Natural Killer Cells (SNK01) in Combination With Trastuzumab or Cetuximab in Subjects With Advanced/Metastatic HER2- or EGFR-Expressing Cancers
Lead sponsor
NKGen Biotech, Inc.
Phase
Phase 1/2
Overall status
Withdrawn
Start date
March 31, 2021
Completion date
February 28, 2023
Enrollment
0 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumor, bladder cancer, cervical cancer, colorectal cancer, egf-r positive non-small cell lung cancer, endometrium cancer, esophageal cancer, head and neck squamous cell carcinoma, her-2 protein overexpression, her2-positive breast cancer, her2-positive gastric cancer, metastatic cancer, non small cell lung cancer, ovarian cancer, pancreatic cancer, sarcoma, triple negative breast cancer